Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

llion ($15 million per year) over the two years beginning with the first commercial sale of DIFICID. Cubist is also eligible to receive an additional $5 million in the first year after first commercial sale and $12.5 million in the second year of the agreement if mutually agreed upon annual sales targets are achieved, as well as a portion of Optimer's gross profits from any sales above the specified annual sales target levels.

Scheduled Conference Call

Optimer will host a conference call today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the outcome of the Anti-Infective Drugs Advisory Committee as well as the Cubist collaboration. To participate in the conference call, please dial (877) 280-7280 from the U.S., or (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Conference Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. 

About DIFICID™ (Fidaxomicin)

DIFICID™ (fidaxomicin) is an investigational antibiotic with a novel mechanism of action, which inhibits the bacterial enzyme RNA polymerase, resulting in the rapid killing of C. difficile. The narrow-spectrum profile of DIFICID eradicates C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics used to treat CDI, metronidazole and vancomycin, have been shown to disrupt the gut flora. DIFICID facilitates the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence rates. In two Phase 3 trials for the treatment of CD
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
(Date:3/27/2015)... /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces ... grant of an aggregate of 236,070 options to certain ... the Company pursuant to the Company,s Stock Option Plan. ... the tenth anniversary of the date of grant, 5,000 ... the date of grant and 50,000 are set to ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies ... the field of holographic medical imaging, is entering the ... Kickstarter campaign. Launching on April 20 th , 2015, ... Voxbox Pro. The 8-inch and 22-inch displays will allow ... for the first time. In addition to the two ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
...  ECR Booth #313/Expo C -- Varian Medical Systems, Inc. ... detectors for fluoroscopy, angiography, cardiology and cone-beam CT imaging ... in Vienna, Austria, from March 1- 5, 2012.    ... to continuous product improvement," said Stephen Kimmel, vice president ...
... SAN DIEGO, Feb. 29, 2012  Marshall Edwards, Inc. (Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... Chief Executive Officer, will present an update on Marshall ... drug candidates, ME-143 and ME-344, at the Roth Capital ...
Cached Medicine Technology:Varian Medical Systems to Exhibit X-Ray Tubes and Flat Panel Detector Technology Enhancements to Improve Digital Imaging at the ECR Annual Meeting 2Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference 2
(Date:3/27/2015)... On February 21, 2015, Choices ... Stardust Penthouse on the rooftop of the luxurious ... sustainable product TV and film placement producer, was ... which featured some of the world’s top providers ... services. , “We were honored to have a ...
(Date:3/27/2015)... While deep learning was the topic of many ... , the CEO of one start-up spoke passionately about using ... well beyond the generally-agreed ceiling of 120 years. , Insilico ... of 12 companies recognized as the hottest GPU-powered startups in ... GTC Emerging Companies Summit have business models focused on ...
(Date:3/27/2015)... LONDON, UK (PRWEB) March 27, 2015 ... SiteStart Melissa (Liss) Easy was named to the 2015 ... 40 Under 40 list spotlights 40 dynamic, up-and-coming leaders ... accomplishments and community involvement. Winners are honored at an ... supplement of the Philadelphia Business Journal. , Lyn Kremer, ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global MEMS pressure ... MEMS based ultra-miniature pressure sensor designed especially for the ... 220um x 75um provides ample space for 1-French catheter ... industry leading in vivo drift performance of 2 ... pressure range from 0 to 1,100 mmHg absolute. ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2
... usual statement – often recommended by the doctors to the ... now a new study by researchers at Fox// Chase Cancer ... early-stage prostate cancer live longer if the disease is treated ... ,Researchers have found that patients (aged 65 to ...
... drinking and smoking could be damaging to health, but ... to cardiovascular diseases and// certain cancers reducing a person’s ... government medical advisor. ,Ken Snider, advisor at ... said that the problem was not only to do ...
... Research UK has suggested that certain Christmas toys are not ... 14 toys out of the 15 that// were tested, turned ... safety limits of 85 decibels. ,Among the ... included a mechanical toy machine gun, a plastic tommy gun ...
... drinking, which can be likened to about two to four ... for women, may actually be a way to live// longer. ... of death, Italian researchers have said. ,Researchers opined ... but people who already regularly consume low to moderate amounts ...
... Fetal and early childhood exposures to industrial chemicals in ... lead to neurodevelopmental disorders (NDDs)—autism,// attention deficit disorder (ADHD), ... done to identify the individual chemicals that can cause ... ,In a new review study, published in the print ...
... papers accepted for publication in the Journal of ... new patient information// provided by The Hormone Foundation, ... , Lifestyle Accelerates Testosterone Decline ... decline with age, but a new study confirms ...
Cached Medicine News:Health News:Ways to Fight Childhood Obesity 2Health News:Toy Story Turns Bitter-Christmas Toys, No Music to the Ears! 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 3Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 4Health News:Testosterone Decline in Men Linked to Lifestyle, Increases in Obese Girls 2
... Stereo Fundus Lens is specifically designed for ... retina. Its enhanced 3-D stereoscopic design enables ... detail, making it ideal for detecting changes ... serous detachments and other macular abnormalities. It ...
The Volk 30D is designed to provide the practitioner a wide field of view with a short working distance. This lens is excellent for use with small pupils....
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
Medicine Products: